HUNGARIAN PATENT OFFICE

Translation
NOVELTY SEARCH REPORT

Application No.: **P 99 04368**

Category	PCT	Identification data of the relevant documents	Relevant No. of claims	International classification of the application NSZO 6
X		HU 208089 B	1-55.	C07K 1447 C07K 706
X	*	Archivum Immunologiae et Therapie Experimentalis vol. 39, no. 5-6, pages 461-467	1.,8.,18., 23.,24.,31., 33.,42.,45., 50	C07K 114 A61K 3520 A61K 3808 A61P 2528
X	*	Unlisted Drugs vol. 41, no. 3, page 52e	1.,2.,8.,9., 42-44.	
X	*	The Biochemical Journal, vol. 199, no. 1, pages 9-15	48., 49	
X	*	Febs Letters vol. 49,. no. 2, pages 276-279	48.	
Y	*	Archivum Immunologiae et Therapiae Experimentalis vol. 41, no. 5-6, pages 275-279	12.,22.,26., 32	

Technical field searched
C07K
A61K
A61P

Date: 05.06.2000

Search performed by the Examiner
Ozvald I.

---

* From the PCT-Search Report
Categories of relevant documents:
X: document disclosing all features of the invention;
Y: document, if combined with one or two documents (of the same category) disclosing all features of the invention;
A: document disclosing the state of art;
O: document relating to public use, application, oral communication, exhibition or available to the public in any other way (intermediate document)
P: earlier patent document but published on or after the priority date;
E: Hungarian patent or utility model specification published subsequent to priority date of the examined application;
D: document cited by Applicant in the state of art, part of the specification of the examined application;
&: analogous document, member of the same patent family

MAGYAR SZABADALMI HIVATAL
Budapest V., Garibaldi utca 2. • 1370 Budapest 5, Pf. 552
Telefon: 312 4400 • Telefax: 131 2596
Ac. szám: 15311746201 SZJ 15 Közigazgatás

2000 JÚN 06.

Ügyiratszám:
P9904368 /7
Ügyintéző:
Ozvald I./Berger E.
13761 Vu

Kovári György, ADVOPATENT
Szabadalmi Iroda

Budapest
Fő u. 19.
1011

Tárgy: Értesítés újdonságkutatás elvégzéséről (A3)

ÉRTESÍTÉS

Bejelentők:
Georgiades Biotech Limited, Road Town/Tortola, British Virgin Islands (GB)
Ludwick Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Wroclaw (PL)

Képviselő:
Kovári György, ADVOPATENT Szabadalmi Iroda

A találmány címe:
Colostrinin és alkalmazása

A bejelentés napja: 1997. október 3.

A közzététel napja: 2000. június 28.

A Magyar Szabadalmi Hivatal az 1995. évi XXXIII. törvény (Szt.) 69.§-ának (4) bekezdése alapján az újdonságkutatás elvégzéséről hatósági tájékoztatást közöl a Szabadalmi Közlöny és Védjegyértesítő 2000. évi 7. számában,

2000. július 28. napján.

Egyben a Hivatal az Szt. 69.§-ának (3) bekezdése alapján az újdonságkutatási jelentést a hivatkozott iratok másolataival együtt megküldi a bejelentőnek.

A Hivatal egyúttal tájékoztatja a bejelentőt, hogy az **érdemi vizsgálatot** - ha korábban nem kérték - legkésőbb az újdonságkutatás elvégzéséről közölt hatósági tájékoztatás fent megjelölt napjától számított **hat hónap elteltéig** lehet kérni.

Az érdemi vizsgálatra irányuló kérelem elmaradása esetén úgy kell tekinteni, hogy a bejelentő lemondott az ideiglenes szabadalmi oltalomról.

Budapest, 2000. június 5.

Melléklet: - újdonságkutatási jelentés
1 db hivatkozott irat másolata

Ozvald István
szabadalmi elbíráló

MAGYAR SZABADALMI HIVATAL

ÚJDONSÁGKUTATÁSI JELENTÉS

A bejelentés ügyszáma: **P9904368**

Kat.	PCT	A releváns iratok azonosító adatai	A vonatkozó igénypontok száma	A bejelentés osztályjelzete NSZO6
X		HU 208089 B	1-55.	C07K 1447 C07K 706 C07K 114 A61K 3520 A61K 3808 A61P 2528
X	*	Archivum Immunologiae et Therapie Experimentalis vol. 39, no. 5-6, pages 461-467	1., 8., 18., 23., 24., 31., 33., 42., 45., 50.	
X	*	Unlisted Drugs vol. 41, no. 3, page 52e	1., 2., 8., 9., 42-44.	
X	*	The Biochemical Journal, vol. 199, no. 1, pages 9-15	48., 49.	A vizsgált szakterület NSZO
X	*	Febs Letters vol. 49, no. 2, pages 276-279	48.	C07K A61K A61P
Y	*	Archivum Immunologiae et Therapiae Experimentalis vol. 41, no. 5-6 pages 275-279	12., 22., 26., 32.	

Dátum: 2000.06.05 **Ügyintéző:**

* PCT-újdonságkutatási jelentésből

A releváns iratok kategóriái:

X: olyan irat, amely a vizsgált megoldás valamennyi lényeges jellemzőjét tartalmazza

Y: olyan irat, amely egy vagy két irattal kombinálva magában foglalja a vizsgált megoldás valamennyi lényeges jellemzőjét

A: a technika állását meghatározó irat

O: olyan irat, amely nyilvános gyakorlatbavételre, használatra, szóbeli közlésre, kiállításra vagy más módon történő ismertetésre utal

P: olyan irat, amely a magyar bejelentés napja előtt, de az igényelt elsőbbség napján vagy azt követően került nyilvánosságra

E: olyan korábbi elsőbbségű magyar szabadalmi vagy használati mintaoltalmi leírás, amely a vizsgált bejelentés elsőbbségi napját követően került nyilvánosságra

D: olyan irat, amelyet a vizsgált megoldás leírásában a technika állásának ismertetésénél a bejelentő idéz

&: azonos szabadalmi családba tartozó irat /analóg/

Érvényesség: [redacted]

Bejelentés ügyszáma:	**P8902524**	Bejelentés napja:	19890418
		Adatközlés napja:	19910429
Közzétételi szám:	55244	Közzététel napja:	19910528
Lajstromszám:	**208089**	Megadás napja:	19930510
		Megadás meghirdetése:	19930830

Elsőbbségi adatok: DEP3813043 - 19880419, EP88118243 - 19881102
PCT bejelentés száma: PCT/DE 89/00233
PCT közzététel száma: WO 89/10139
NSZO: **A61K-039/395**

Magyar cím:
Eljárás immunglobulin koncentrátumok és ezeket tartalmazó gyógyszerkészítmények előállítására
Angol cím:
PROCESS FOR PRODUCING IMMUNEGLOBULIN CONCENTRATES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

Bejelentő:
Biotest Pharma GmbH., Dreieich, DE
Feltaláló:
Dichtelmüller, Herbert, Sulzbach, DE
Stephan, Wolfgang, Dreieich, DE
Lissner, Reinhard, Weilbach, DE
Arndt, Rüdiger, Hamburg-Blankenese, DE
Képviselő:
S.B.G. és K. Ügyvédi és Szabadalmi Iroda, Budapest

Kivonat:
A találmány tárgya eljárás immunglobulin hatóanyag előállítására nem-immunizált szarvasmarhák előtejéből (colostrum). A hatóanyag immunglobulin-tartalma magas, ugyanakkor antikomplementer-aktivitása alacsony. Embernek orálisan, állatoknak intravénásan is adható önmagában vagy gyógyszerkészítmény alakjában baktériumok- vagy toxinok-okozta betegségek, különösen az AIDS-betegek vagy más immunhiányban szenvedők súlyos hasmenése, az "utazók hasmenése", a csecsemők toxin-okozta hasmenése, gyomor- és nyombélfekélyek, krónikus és akut Yersinia-fertőzések vagy protozoonok okozta megbetegedések kezelésére.

Igénypont:
1. Eljárás immunglobulin hatóanyag előállítására szarvasmarhák ellés utáni 30, előnyösen 10 órán belül kifejt előtejéből (a colostrumból), az előtej desztillált vízzel történő hígításával, a hígított előtej pasztőrözésével, a tejzsír eltávolításával és a kazein kicsapásával és eltávolításával, azzal jellemezve, hogy az így kapott előtejsavót 145-180 °C bemeneti, és 65-70 °C kimeneti hőmérséklet mellett porlasztva szárítjuk. (Elsőbbsége: 1988. 04. 19.)

2. Az 1. igénypont szerinti eljárás, azzal jellemezve, hogy az előtejsavót a porlasztva szárítás előtt töményítjük. (Elsőbbsége: 1988. 04. 19.)

3. Az 1. vagy a 2. igénypont szerinti eljárás, azzal jellemezve, hogy az előtejsavót a porlasztva szárítás előtt oktánsavval kezeljük. (Elsőbbsége: 1988. 04. 19.)

4. Eljárás bakteriális, protozoa eredetű vagy toxinok okozta megbetegedések, gyomor- és bélbetegségek vagy immunhiányos állapotok kezelésére alkalmas gyógyászati készítmény előállítására, azzal jellemezve, hogy az 1-3. igénypontok bármelyike szerint előállított hatóanyagot önmagában vagy a szokásos gyógyszerkikészítési segédanyagokkal összekeverve ismert módon formázzuk. (Elsőbbsége: 1988. 11. 02.)

Abstract
The subject of the invention relates to the production of immuneglobulin active agent from the foremilk (colostrum) of cattle. The immuneglobulin content of the active ingredient is high, but at the same time its anti-complementary activation is low. It may be administered orally for humans and intravenously for animals on its own or in the form of a pharmaceutical preparation for the treatment of bacteria or toxin-caused illnesses, serious diarrhoea of AIDS patients or of patients suffering from other immune deficiency diseases, "traveller's diarrhoea", toxin-caused diarrhoea in infants, stomach and duodenal ulcers, chronic and acute Yersinia infections or illnesses caused by protozoa.

Claims:

1. Procedure for the production of immuneglobulin active agent from the foremilk (colostrum) of cattle taken within 30 hours, favourably 10 hours, of giving birth by the dilution of the foremilk in distilled water, pasteurising the diluted foremilk, the removal of the milk fat, and the precipitation and removal of the casein characterised by that the lactic acid obtained from the foremilk is spray dried with an input temperature of 145-180 °C and an output temperature of 65-70 °C. (Priority: 19/04/1988)
2. The procedure according to claim 1 characterised by that the foremilk lactic acid is concentrated before spray drying. (Priority: 19/04/1988)
3. The procedure according to claims 1 or 2 characterised by that the foremilk lactic acid is treated with caprylic acid before spray drying. (Priority: 19/04/1988)
4. Procedure for the production of a medial preparation suitable for the treatment of bacteria, protozoa or toxin caused illnesses, stomach and intestine illnesses or immune deficiency conditions characterised by that any of the active agents produced according to any of the claims 1-3 is formed mixed with the usual pharmaceutical preparation auxiliary materials or on its own. (Priority: 02/11/1988)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)
PAC/18434		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB97/02721	03/10/1997	03/10/1996
International Patent Classification (IPC) or national classification and IPC		
C07K14/47		
Applicant		
LUDWICK HIRSZFELD INSTITUTE OF ..... et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
01/05/1998	03.02.99
Name and mailing address of the IPEA/	Authorized officer
European Patent Office D-80298 Munich Tel. (+49-89) 2399-0 Tx. 523656 epmu d Fax. (+49-89) 2399-4465	Donath, C Telephone No (+49-89) 2399-8710

Form PCT/IPEA/409 (Cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB97/02721

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-21 as originally filed

Claims, No.:

1-55 as originally filed

Drawings, sheets:

1/1 as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2-7,9-17,19-22,25-30,32,34-41,43,46,47,51-55
	No:	Claims	1,8,18,23,24,31,33,42,44,45,48,49,50
Inventive step (IS)	Yes:	Claims	3-7,10,11,13-17,20,21,25,27-30,36-41,46,47,53
	No:	Claims	1,2,8,9,12,18,19,22-24,26,31-35,42-45,48-52,54,55
Industrial applicability (IA)	Yes:	Claims	1-55
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Ad section V.:

1. The following documents are cited:
   D1 Archivum Immunologiae et Therapiae Experimentalis 39(5-6), 461-467, 1991
   D2 The Biochemical Journal 199(1), 9-15, 1981
   D3 Archivum Immunologiae et Therapiae Experimentalis 41(5-6), 275-279, 1993

2. The present International application refers to the use of colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system, to a method of preparing colostrinin from mammalian colostrum, to the C-terminal nonapeptide of colostrinin and its use in the manufacture of a medicament.
   In view of the documents cited in the International Search Report only the subject-matter of claims 2-7,9-17,19-22,25-30,32,34-41,43,46,47 and 51-55 of the present International application has to be regarded as being new (Article 33(2) PCT).

2.1 D1 describes the effect of a proline-rich polypeptide (PRP), isolated from ovine colostrum, on the development of autoimmune anaemia and survival of New Zealand Black (NZB) mice. It could be shown that PRP significantly reduces the percentage of mice exhibiting positive Coombs reaction and prolonged life of these mice. PRP, given at a very broad range of doses, was efficient in lowering the incidence of haemolytic anaemia in NZB mice. The results shown in D1 indicated that PRP affected condition of NZB mice by restoring suppressor T cell function and thus, PRP have therapeutical value and can be used in the treatment of autoimmune disorders (see D1, p.461-462, 'Abstract' and 'Introduction', p.464-466, 'Discussion').
   Therefore, in view of the disclosure of D1 the subject-matter of claims 1,8,18,23,24,31,33,42,44,45 and 50 is not new.

2.2 D2 discloses the chemical and physical characterization of PRP from ovine colostrum. A detailed purification process for PRP is outlined in the document (see D2, p.1981,'Isolation of proline-rich polypeptide').
   Thus, claims 48 and 49 lack novelty.

3. The closest prior art to evaluate the inventiveness of claims 2-7,9-17,19-22,25-

30,32,34-41,43,46,47 and 51-55 of the present International application is also the above cited document D1.

3.1 Claims 2,9,19 and 43 concern the use of colostrinin as a medicament for humans and claims 34 and 35 refer to a pharmaceutical composition comprising colostrinin in different application forms.
As outlined above ovine colostrinin has been used in the treatment of chronic disorders of the immune system of mice.
For a person skilled in the art it is a straight forward procedure to go on and to develop a medicament for humans based on the results from mice. It is merely a common procedure that a compound first will be tested in animal experiments before it will be applied to humans in clinical studies. As well it is common knowledge that a pharmaceutical composition can be prepared in different forms depending on its intended application such as in a form suitable for absorption or as a tablet, gel or plaster etc..

Claims 12,22,26 and 32 refer to colostrinin derived from a non-ovine source, and claims 51,52,54 and 55 refer to a nanopeptide of colostrinin for use as a medicament or being comprised in a pharmaceutical composition.
D3 describes an active nonapeptide fragment isolated from the products of PRP digestion or obtained by chemical synthesis. Said nonapeptide shows full spectrum of biological activities of PRP and it is assumed that this nonapeptide may have a therapeutic value, especially in cases of autoimmune disorders. Moreover, D3 discloses that PRPs have been found in other sources, such as dog colostrum, human and bovine milk, parotid-gland saliva (see D3, p.275,'Abstract', p.277-279, 'The Relationship between the Structure of PRP and its activity').
For a person skilled in the art it is merely a common procedure to combine the teachings of D1 and D3, and thus to use the nonapeptide instead of the PRP as a medicament or in a pharmaceutical composition.

Therefore, claims 2,9,12,19,22,26,32,34,35,43,51,52,54 and 55 are considered to lack an inventive step.

3.2 However, in the prior art no indication has been given that colostrinin can be used in the treatment of chronic disorders of the central nervous system, in the

treatment of diseases with a bacterial and viral aetiology or in the treatment of acquired immunological deficiencies. Moreover, in the prior art no indication has been given for the use of colostrinin as a dietary supplement or for use as a prophylactic medicament for humans to prevent or inhibit the development of Alzheimer's disease.
Therefore, an inventive step has to be acknowledged for claims 3-7,10,11,13-17,20,21,25,27-30,36-41,46,47 and 53 of the present International application (Article 33(3) PCT).

Ad section VIII.:

1. Claim 45 lacks clarity due to the expression "prophylactic medicament". A drug can be used as a medicament in general or the drug can be used as a prophylactic medicament for a certain diseases, but not prophylactical in general.

2. The applicant is asked to check the references of claims 10 and 11. Furthermore, the applicant is asked to check the numbering of the claims, because there are two claims being numbered "44".

3. The present International application contains an unacceptable number of independent claims. Therefore, the requirements of Article 6 PCT regarding conciseness of claims has not been met. In this context, the attention of the applicant is drawn to the fact that undue repetition of wording between one claim and another should be avoided by use of the dependent form.

4. With respect to claims 23-30 you are already informed that in case of an European application said claims are not allowable because, "methods of treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body shall not be regarded as inventions which are susceptible of industrial application."

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
PAC/18434		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 97/02721	03/10/1997	03/10/1996
Applicant		
LUDWICK HIRSZFELD INSTITUTE OF ..... et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. [X] **Certain claims were found unsearchable** (see Box I).

2. [ ] **Unity of invention is lacking** (see Box II).

3. [ ] The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing
   - [ ] filed with the international application.
   - [ ] furnished by the applicant separately from the international application,
     - [ ] but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
   - [ ] *Transcribed by this Authority*

4. With regard to the **title,**
   - [X] the text is approved as submitted by the applicant.
   - [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**
   - [X] the text is approved as submitted by the applicant.
   - [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is:

   Figure No. _____
   - [ ] as suggested by the applicant.
   - [ ] because the applicant failed to suggest a figure.
   - [ ] because this figure better characterizes the invention.
   - [X] None of the figures.

INTERNATIONAL SEARCH REPORT

tional application No.
PCT/GB 97/02721

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 23-30,42 and 43 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02721

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/47 C07K7/06 C07K1/14 A61K35/20 A61K38/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	INGLOT A.D. ET AL.: "Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leucocytes" ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 44, no. 4, August 1996, pages 215-224, XP002055880	1-11, 13-21, 23-25, 27-31, 33-47, 50-55
Y	see the whole document	12,22, 26,32
	--- -/--	

[X] Further documents are listed in the continuation of box C.

[ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
17 February 1998	04.03.98
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Donath, C

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZIMECKI M. ET AL.: "Effect of a proline-rich polypeptide (PRP) on the development of hemolytic anemia and survival of new zealand black (NZB) mice" ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 39, no. 5-6, 1991, pages 461-467, XP002055881 see the whole document ---	1,8,18, 23,24, 31,33, 42,45,50
X	"PRP" UNLISTED DRUGS, vol. 41, no. 3, 1989, page 52e XP002055882 see the whole document ---	1,2,8,9, 42-44
X	JANUSZ M. ET AL.: "Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum" THE BIOCHEMICAL JOURNAL, vol. 199, no. 1, 1981, pages 9-15, XP002055883 see page 9, right-hand column, paragraph 1 - page 11, left-hand column, paragraph 7 ---	48,49
X	JANUSZ M. ET AL.: "Isolation and characterization of a proline-rich polypeptide from ovine colostrum" FEBS LETTERS, vol. 49, no. 2, 1974, pages 276-279, XP002055884 see the whole document ---	48
Y	JANUSZ M. AND LISOWSKI J.: "Proline-rich polypeptide (PRP) - an immunomodulatory peptide from ovine colostrum" ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, vol. 41, no. 5-6, 1993, pages 275-279, XP002055885 see page 277, right-hand column, line 3 - page 279, left-hand column, line 7 -----	12,22, 26,32

1

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 30 June 1998 (30.06.98)	
International application No. PCT/GB97/02721	**Applicant's or agent's file reference** PAC/18434
International filing date (day/month/year) 03 October 1997 (03.10.97)	**Priority date** (day/month/year) 03 October 1996 (03.10.96)
Applicant JANUSZ, Marin et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

01 May 1998 (01.05.98)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer S. Mafla
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38